RhumbLine Advisers
QNRX

RhumbLine Advisers’s Quoin Pharmaceuticals QNRX Stock Holding History

RhumbLine Advisers’s Portfolio QNRX Stock Details QNRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.3K Buy
2,332
+811
+53% +$4.38K ﹤0.01% 3887
2026
Q1 		$10K Sell
1,521
-145
-9% -$1.31K ﹤0.01% 3807
2025
Q4 		$24K Buy
1,666
+456
+38% +$6.21K ﹤0.01% 3739
2025
Q3 		$8.7K Sell
1,210
-32
-3% -$249 ﹤0.01% 3869
2025
Q2 		$11.4K Buy
1,242
+49
+4% +$376 ﹤0.01% 3855
2025
Q1 		$9.55K Buy
1,193
+504
+73% +$6.63K ﹤0.01% 3841
2024
Q4 		$15.7K Buy
689
+95
+16% +$2.18K ﹤0.01% 3826
2024
Q3 		$10.5K Buy
594
+171
+40% +$3.6K ﹤0.01% 3883
2024
Q2 		$8.59K Buy
423
+314
+288% +$7.98K ﹤0.01% 4004
2024
Q1 		$3.6K Buy
109
+79
+263% +$7.79K ﹤0.01% 4024
2023
Q4 		$5.13K Buy
30
+4
+15% +$615 ﹤0.01% 3979
2023
Q3 		$3.78K Buy
26
+5
+24% +$1.04K ﹤0.01% 4025
2023
Q2 		$4.33K Buy
+21
New +$4.32K ﹤0.01% 4115

Other funds holding QNRX

DIG
Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SC
SummitTX Capital Fort Worth, Texas $3.89B AUM 55.94% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

RhumbLine Advisers's QNRX Position: Q2 2026 in Review

RhumbLine Advisers increased its Quoin Pharmaceuticals (QNRX) stake by 53% in Q2 2026, buying an estimated $4.38K and bringing the position to 2,332 shares worth $11.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3887.

RhumbLine Advisers first reported a position in QNRX in Q2 2023 and has held it in 13 quarters since. The position peaked at $24K in Q4 2025. 20 funds tracked by Wall St. Rank hold QNRX as of Q2 2026.

  • RhumbLine Advisers held 2,332 shares of Quoin Pharmaceuticals worth $11.3K as of Q2 2026.
  • RhumbLine Advisers bought 811 Quoin Pharmaceuticals shares in Q2 2026, an estimated $4.38K.
  • Quoin Pharmaceuticals made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3887 holding.
  • RhumbLine Advisers first reported a position in Quoin Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
  • RhumbLine Advisers's Quoin Pharmaceuticals position peaked at $24K in Q4 2025.
  • 20 funds tracked by Wall St. Rank held Quoin Pharmaceuticals as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.